Page 92 - 2019_02-Haematologica-web

E. Onecha et al.
confirmed that MRD positive status determined by sequencing was the only statistically significant predictor of the risk of relapse (P=0.012).
In conclusion, we have optimized a new targeted sequencing method with high sensitivity for MRD evalua- tion with applicability in a high percentage of AML patients, improving the capacity, over MFC or qPCR, to predict the survival outcomes of the AML patients in our cohort.
Acknowledgments
This study was supported by the Subdirección General de Investigación Sanitaria (Instituto de Salud Carlos III, Spain) grants PI13/02387 and PI16/01530, and the CRIS against Cancer foun- dation grant 2014/0120. ML holds a postdoctoral fellowship of the Spanish Ministry of Economy and Competitiveness (FPDI-2013- 16409). PRP holds a postdoctoral fellowship of the Spanish Instituto de Salud Carlos III: Contrato Predoctoral de Formación en Investigación en Salud i-PFIS (IFI 14/00008).
References
1. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447.
2. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649.
3. Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136-1152.
4. Ivey A, Hills RK, Simpson MA, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374(5):422-433.
5. Kronke J, Schlenk RF, Jensen KO, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian Acute Myeloid Leukemia Study Group. J Clin Oncol. 2011;29(19):2709-2716.
6. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for child- hood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11(6): 543-552.
7. Balsat M, Renneville A, Thomas X, et al. Postinduction minimal residual disease pre- dicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the Acute Leukemia French Association Group. J Clin Oncol. 2017;35(2):185-193.
8. Zhu HH, Zhang XH, Qin YZ, et al. MRD- directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood. 2013;121(20):4056-4062.
9. Freeman SD, Virgo P, Couzens S, et al. Prognostic relevance of treatment response measured by flow cytometric residual dis- ease detection in older patients with acute myeloid leukemia. J Clin Oncol. 2013;31(32):4123-4131.
10. Terwijn M, van Putten WL, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013;31(31):3889-3897.
11. Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131(12):1275-1291.
12. Grimwade D, Freeman SD. Defining minimal
residual disease in acute myeloid leukemia: which platforms are ready for "prime time"? Hematology Am Soc Hematol Educ Program. 2014;2014(1):222-233.
13. Cedena MT, Rapado I, Santos-Lozano A, et al. Mutations in the DNA methylation path- way and number of driver mutations predict response to azacitidine in myelodysplastic syndromes. Oncotarget. 2017;8(63):106948- 106961.
14. Gorello P, Cazzaniga G, Alberti F, et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia. 2006;20(6):1103-1108.
15. McLaren W, Gil L, Hunt SE, et al. The ensembl variant effect predictor. Genome Biol. 2016;17(1):122.
16. Tomlinson B, Lazarus HM. Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making. Expert Rev Hematol. 2017;10(6):563-574.
17. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079-1089.
18. Thol F, Kolking B, Damm F, et al. Next-gen- eration sequencing for minimal residual dis- ease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 muta- tions. Genes Chromosomes Cancer. 2012;51(7):689-695.
19. Kohlmann A, Nadarajah N, Alpermann T, et al. Monitoring of residual disease by next- generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease. Leukemia. 2014;28(1):129-137.
20. Metzeler KH, Herold T, Rothenberg- Thurley M, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016; 128(5):686- 698.
21. Bullinger L, Dohner K, Dohner H. Genomics of acute myeloid leukemia diagnosis and pathways. J Clin Oncol. 2017;35(9):934-946.
22. Koeffler HP, Leong G. Preleukemia: one name, many meanings. Leukemia. 2017; 31(3):534-542.
23. Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378(13):1189-1199.
24. Klco JM, Miller CA, Griffith M, et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA. 2015;314 (8):811-822.
25. Getta BM, Devlin SM, Levine RL, et al. Multicolor flow cytometry and multigene next-generation sequencing are complemen- tary and highly predictive for relapse in acute myeloid leukemia after allogeneic transplantation. Biol Blood Marrow
Transplant. 2017;23(7):1064-1071.
26. Debarri H, Lebon D, Roumier C, et al. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget. 2015;6(39):
42345-42353.
27. Salipante SJ, Fromm JR, Shendure J, et al.
Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing. Mod Pathol. 2014;27(11):1438-1446.
28. Brunetti C, Anelli L, Zagaria A, et al. Droplet digital PCR is a reliable tool for monitoring minimal residual disease in acute promyelo- cytic lseukemia. J Mol Diagn. 2017;19(3): 437-444.
29. Roloff GW, Lai C, Hourigan CS, et al. Technical advances in the measurement of residual disease in acute myeloid leukemia. J Clin Med. 2017;6(9).
30. Minervini A, Francesco Minervini C, Anelli L, et al. Droplet digital PCR analysis of NOTCH1 gene mutations in chronic lym- phocytic leukemia. Oncotarget. 2016;7(52): 86469-86479.
31. Ossenkoppele G, Schuurhuis GJ. MRD in AML: does it already guide therapy deci- sion-making? Hematology Am Soc Hematol Educ Program. 2016;2016(1):356-365.
32. Cruz NM, Mencia-Trinchant N, Hassane DC, et al. Minimal residual disease in acute myelogenous leukemia. Int J Lab Hematol. 2017;39 (Suppl 1):53-60.
33. Duployez N, Nibourel O, Marceau-Renaut A, et al. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA. Am J Hematol. 2014;89(6): 610-615.
34. Jacobsohn DA, Tse WT, Chaleff S, et al. High WT1 gene expression before haematopoietic stem cell transplant in chil- dren with acute myeloid leukaemia predicts poor event-free survival. Br J Haematol. 2009;146(6):669-674.
35. Hourigan CS, Gale RP, Gormley NJ, et al. Measurable residual disease testing in acute myeloid leukaemia. Leukemia. 2017;31(7): 1482-1490.
36. Rossi G, Carella AM, Minervini MM, et al. Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogene- ic stem cell transplantation: a comparison between multiparameter flow cytometry and Wilms' tumor 1 expression. Leuk Res. 2015;39(2):138-143.
37. Jourdan E, Boissel N, Chevret S, et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013;121(12): 2213-2223.
296
haematologica | 2019; 104(2)